<DOC>
	<DOCNO>NCT03022123</DOCNO>
	<brief_summary>270 untreated patient , age 18 65 year , diffuse large B-cell lymphoma ( B-DLCL ) treat pegylated liposomal doxorubicin ( PL-doxorubicin ) modiÔ¨Åed CHOP-rituximab regimen . PL-doxorubicin 35-40 mg/m ( 2 ) epirubicin 70mg/m ( 2 ) give combination standard dosage prednisone , vincristine , cyclophosphamide , rituximab ( accord CHOP-R regimen ) every 21 day six course .</brief_summary>
	<brief_title>The Study Pegylated Liposomal Doxorubicin Contrast Epirubicin Treatment Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>PL-doxorubicin 35-40 mg/m ( 2 ) epirubicin 70mg/m ( 2 ) give day 1 combination standard dosage prednisone , vincristine , cyclophosphamide ( accord CHOP regimen ) every 21days six course . The choice adopt dosage 30 mg/m2 ( instead 50 mg/m2 conventionaldoxorubicin ) base pharmacokinetic data result previous study lymphoma.Rituximab 375 mg/m2 give day 0 subsequent course therapy . Granulocyte colony-stimulating factor give presence grade 4 neutropenia febrile neutropenia hematological recovery . Treatment stop lymphoma progress , patient refuse participation , intercurrent clinical condition adverse event .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age 18 65 year Diagnosis previouslyuntreated DLBCL ( patient transform untreated lowgrade lymphoproliferative disease accept ) ECOG performance status &lt; 3 ( high due lymphoma ) No symptomatic cardiac arrythmias heart failure Acceptable renal , hepatic pulmonary function Standard laboratory radiological staging procedure leave ventricular ejection fraction analysis echocardiography scintigraphy require therapy case The protocol approve ethic review committee partici pat center All patient give inform write consent . Patients previous history cardiac disease ; HIVHBsAgHCV positivity , central nervous system involvement major clinicalcondition ; Other lymphoma , might preclude regular therapeutic course , exclude study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>